Trending Topics


Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.
Wednesday, December 19, 2018
Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.
Monday, December 3, 2018
The world’s most comprehensive hematology meeting of the year will take place in San Diego, California, from December 1 through 4. Memorial Sloan Kettering experts are available to comment on research and breaking news out of the meeting. Follow the meeting live on Twitter using the hashtag #ASH18. For more information and to set up interviews or access photos and video, email Rebecca Williams at
Thursday, November 29, 2018

See all trending topics Arrow rightAn icon showing an arrow pointing to the right.

Press Releases


Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.
Sunday, December 2, 2018
Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.
Friday, November 23, 2018
Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).
Sunday, October 21, 2018

See all press releases Arrow rightAn icon showing an arrow pointing to the right.

On Our Blog


Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.
Thursday, January 17, 2019
One size does not fit all when it comes to treating renal cell carcinoma.
Tuesday, January 15, 2019
Learn how to get enough calories during treatment from MSK specialists in diet and nutrition.
Tuesday, January 15, 2019

See all blog posts Arrow rightAn icon showing an arrow pointing to the right.

Media Coverage


The findingspublished on January 14 in Nature Genetics, are the latest line of evidence to suggest that tumours with a large number of DNA mutations are more likely to respond to immunotherapies than are cancers with fewer mutations — and result in longer survival for people who receive treatment. Study coauthor, MSK’s Luc Morris is featured.
Tuesday, January 15, 2019
The health-care industry is preparing for a new law that researchers say will mean more treatments for pediatric cancers, which are the leading cause of death from disease among children. The drug, Idasanutlin, will also be tested this year on children at Memorial Sloan Kettering Cancer Center.
Tuesday, January 15, 2019
Experiments involving just a few patients have hinted at it, and research on one type of tumor at a time has supported it, but a large study has now delivered the strongest evidence yet about how to identify cancer patients who are likely to benefit from a particular form of immunotherapy: count. MSK’s Timothy Chan, one of the lead authors of the study is featured.
Monday, January 14, 2019

See all media coverage Arrow rightAn icon showing an arrow pointing to the right.

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
Emily O'Donnell
Media Relations Manager, Surgery
Courtney Nowak
Media Relations Manager, Regional Care Network
Caitlin Hool
Senior Manager, Media Relations and Partnerships
Nicole H. McNamara
Senior Media Strategist
Rebecca Williams
Media Strategist
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.